The present disclosure provides technology that can ensure excellent visibility when introducing an embolization agent and that reduces the visibility of said agent after introduction. Provided is an embolization agent having a hydrogel which contains a visualizing agent, and a reaction product of an ethylenically unsaturated monomer, a crosslinking agent, and, as necessary, a bifunctional monomer, where the swelling ratio of the embolization agent is 5-300 times, and the post-swelling CT number of the embolization agent is 50-300 HU and falls below the pre-swelling CT number of the embolization agent.

The present disclosure provides technology that can ensure excellent visibility when introducing an embolization agent and that reduces the visibility of said agent after introduction. Provided is an embolization agent having a hydrogel which contains a visualizing agent, and a reaction product of an ethylenically unsaturated monomer, a crosslinking agent, and, as necessary, a bifunctional monomer, where the swelling ratio of the embolization agent is 5-300 times, and the post-swelling CT number of the embolization agent is 50-300 HU and falls below the pre-swelling CT number of the embolization agent.

In an embodiment, a method of producing a radiopaque stent graft is provided. The method may include functionalizing a surface of a coating layer of a stent graft to produce a functionalized surface; disposing a tie layer over the functionalized exterior surface of the stent graft; disposing an adherent layer over the tie layer; etching a slot into the adherent layer; functionalizing the slot; and positioning a radiopaque marker in the slot to produce a filled slot and thereby produce the radiopaque stent graft.

In an embodiment, a method of producing a radiopaque stent graft is provided. The method may include functionalizing a surface of a coating layer of a stent graft to produce a functionalized surface; disposing a tie layer over the functionalized exterior surface of the stent graft; disposing an adherent layer over the tie layer; etching a slot into the adherent layer; functionalizing the slot; and positioning a radiopaque marker in the slot to produce a filled slot and thereby produce the radiopaque stent graft.

An object of the present invention is to provide a Zr—Nb-based alloy material as a low-magnetic susceptibility alloy having a high corrosion resistance while maintaining a magnetic susceptibility equivalent to or less than the magnetic susceptibility of the biological alloy of the related art, a method for manufacturing the alloy material, and a Zr—Nb-based alloy product. The Zr—Nb-based alloy material according to the present invention includes, as a chemical composition, 3% by mass or more and 18% by mass or less of Nb, 12% by mass or less of Ti, 6% by mass or less of Cr, 6% by mass or less of Cu, 5% by mass or less of Bi, and a remainder consisting of Zr and unavoidable impurities, in which isothermal ω phase particles are dispersed and precipitated in β phase crystal grains of a parent phase.

Embolization compositions and methods for controlling undesired bleeding and other treatments are provided. Preferred composition may comprise (a) a crosslinked hydrogel material; and (b) a fiber material, wherein the composition comprises a plurality of macropores; and the hydrogel material and fiber material are bonded by covalent and/or non-covalent bonds.

The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.

The present invention provides new classes of phenol compounds, including those derived from tyrosol and analogues, useful as monomers for preparation of biocompatible polymers, and biocompatible polymers prepared from these monomeric phenol compounds, including novel biodegradable and/or bioresorbable polymers. These biocompatible polymers or polymer compositions with enhanced bioresorbabilty and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic formulations. The invention also provides methods for preparing these monomeric phenol compounds and biocompatible polymers.

An implantable device, including: a tube including a plurality of biodegradable biometallic wires braided together, the tube being coated with a flexible conformal biodegradable polymer in an expanded state such that, upon compression and release of compression, the flexible conformal biodegradable polymer-coated tube self-expands back to the expanded state.

An implantable device, including: a tube including a plurality of biodegradable biometallic wires braided together, the tube being coated with a flexible conformal biodegradable polymer in an expanded state such that, upon compression and release of compression, the flexible conformal biodegradable polymer-coated tube self-expands back to the expanded state.